| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Yanyun Sun, Xiao-Jun Lu, Xinghui Fu, Ye Zhang, Yan Zhan, Jiabing Liu, Lingxia Zhao, Chun-Lin Xi. Engrafted primary type-2 astrocytes improve the recovery of the nigrostriatal pathway in a rat model of Parkinson's disease. Molecular and cellular biochemistry. vol 476. issue 2. 2021-07-19. PMID:33070275. |
parkinson's disease (pd) is a disorder characterized by a progressive loss of the dopaminergic neurons in the substantia nigra and a depletion of the neurotransmitter dopamine in the striatum. |
2021-07-19 |
2023-08-13 |
rat |
| Rayul Wi, Young Cheul Chung, Byung Kwan Ji. Functional Crosstalk between CB and TRPV1 Receptors Protects Nigrostriatal Dopaminergic Neurons in the MPTP Model of Parkinson's Disease. Journal of immunology research. vol 2020. 2021-07-12. PMID:33062722. |
mptp induced a significant loss of nigrostriatal dopamine neurons and glial activation in the substantia nigra (sn) and striatum (str) as visualized by tyrosine hydroxylase (th) or macrophage antigen complex-1 (mac-1) or glial fibrillary acidic protein (gfap) immunocytochemistry, respectively. |
2021-07-12 |
2023-08-13 |
mouse |
| Bruk Getachew, Antonei B Csoka, Amna Bhatti, Robert L Copeland, Yousef Tizab. Butyrate Protects Against Salsolinol-Induced Toxicity in SH-SY5Y Cells: Implication for Parkinson's Disease. Neurotoxicity research. vol 38. issue 3. 2021-07-09. PMID:32572814. |
parkinson's disease (pd), a progressive neurodegenerative disorder, is associated with the destruction of dopamine neurons in the substantia nigra (sn) and the formation of lewy bodies in basal ganglia. |
2021-07-09 |
2023-08-13 |
human |
| Rebecca D Howell, Sergio Dominguez-Lopez, Sarah R Ocañas, Willard M Freeman, Michael J Beckstea. Female mice are resilient to age-related decline of substantia nigra dopamine neuron firing parameters. Neurobiology of aging. vol 95. 2021-07-09. PMID:32846275. |
female mice are resilient to age-related decline of substantia nigra dopamine neuron firing parameters. |
2021-07-09 |
2023-08-13 |
mouse |
| Atsushi Takeda, Masahiko Tomiyama, Ritsuko Hanajim. [The Relationship Between Pathophysiology and Neurotransmitters in Parkinson's Disease]. Brain and nerve = Shinkei kenkyu no shinpo. vol 73. issue 7. 2021-07-09. PMID:34234041. |
the major motor symptoms of pd are mainly caused by dopamine (da) deficiency due to the loss of dopaminergic neurons in the substantia nigra. |
2021-07-09 |
2023-08-13 |
Not clear |
| Yiqiu Liu, Junyu Deng, Ye Liu, Wei Li, Xuqiang Ni. FGF, Mechanism of Action, Role in Parkinson's Disease, and Therapeutics. Frontiers in pharmacology. vol 12. 2021-07-09. PMID:34234672. |
the death or dysfunction of dopaminergic neurons in the dense part of the substantia nigra leads to dopamine deficiency in the basal ganglia and motor dysfunction. |
2021-07-09 |
2023-08-13 |
Not clear |
| Steven Vetel, Laura Foucault-Fruchard, Claire Tronel, Frédéric Buron, Jackie Vergote, Sylvie Bodard, Sylvain Routier, Sophie Sérrière, Sylvie Chalo. Neuroprotective and anti-inflammatory effects of a therapy combining agonists of nicotinic α7 and σ1 receptors in a rat model of Parkinson's disease. Neural regeneration research. vol 16. issue 6. 2021-07-03. PMID:33269756. |
although no effect was noticed in the amphetamine-induced rotation test, our data has shown that the pha/pre treatment induced partial protection of the dopaminergic neurons (15-20%), assessed by the dopamine transporter density in the striatum and immunoreactive tyrosine hydroxylase in the substantia nigra. |
2021-07-03 |
2023-08-13 |
rat |
| Zhuang-Yao D Wei, Ashok K Shett. Treating Parkinson's disease by astrocyte reprogramming: Progress and challenges. Science advances. vol 7. issue 26. 2021-07-02. PMID:34162545. |
such in vivo astrocyte reprogramming in the mouse model of pd has successfully added new dopaminergic neurons to the substantia nigra and increased dopamine levels associated with axonal projections into the striatum. |
2021-07-02 |
2023-08-13 |
mouse |
| Khadga Raj, G D Gupta, Shamsher Sing. l-Theanine ameliorates motor deficit, mitochondrial dysfunction, and neurodegeneration against chronic tramadol induced rats model of Parkinson's disease. Drug and chemical toxicology. 2021-07-02. PMID:34210222. |
parkinson's disease (pd) is the second most prevalent progressive neurodegenerative disease, characterized by loss of dopaminergic neurons in substantia nigra, with deficiency of dopamine in the striatum. |
2021-07-02 |
2023-08-13 |
rat |
| Maritza Oñate, Alejandra Catenaccio, Natalia Salvadores, Cristian Saquel, Alexis Martinez, Ines Moreno-Gonzalez, Nazaret Gamez, Paulina Soto, Claudio Soto, Claudio Hetz, Felipe A Cour. The necroptosis machinery mediates axonal degeneration in a model of Parkinson disease. Cell death and differentiation. vol 27. issue 4. 2021-06-29. PMID:31591470. |
parkinson's disease (pd) is the second most common neurodegenerative condition, characterized by motor impairment due to the progressive degeneration of dopaminergic neurons in the substantia nigra and depletion of dopamine release in the striatum. |
2021-06-29 |
2023-08-13 |
mouse |
| Nabeel Ali, Amna Syeda, Tenzin Topgyal, Naseem Gaur, Asimul Isla. Parkinson's disease: A current perspectives on Parkinson's disease and key bioactive natural compounds as future potential drug candidates. Current drug targets. 2021-06-24. PMID:34165406. |
the hallmark of pd includes dopamine deficiency (neurotransmitter imbalance) due to the gradual loss of dopaminergic nerves in the substantia nigra in the midbrain. |
2021-06-24 |
2023-08-13 |
Not clear |
| Fang Luo, Sushan Luo, Wenjing Qian, Lin Zhang, Chen Chen, Meimei Xu, Guangling Wang, Zhongfeng Wang, Jian Wang, Wenyuan Wan. Developmental deficits and early signs of neurodegeneration revealed by PD patient derived dopamine neurons. Stem cell research. vol 49. 2021-06-21. PMID:33059129. |
parkinson's disease (pd) is the second most common neurodegenerative disease affecting millions of elder people due to the degeneration of dopamine neurons in the striatum and substantia nigra. |
2021-06-21 |
2023-08-13 |
human |
| Emmi Pakarinen, Tatiana Danilova, Vootele Võikar, Piotr Chmielarz, Petteri Piepponen, Mikko Airavaara, Mart Saarma, Maria Lindah. MANF Ablation Causes Prolonged Activation of the UPR without Neurodegeneration in the Mouse Midbrain Dopamine System. eNeuro. vol 7. issue 1. 2021-06-18. PMID:32005751. |
in our mouse model, increased upr activation did not lead to neuronal cell loss in the substantia nigra (sn), decrease of striatal dopamine or behavioral changes of manf-deficient mice. |
2021-06-18 |
2023-08-13 |
mouse |
| E Hill, R Gowers, M J E Richardson, M J Wal. α-Synuclein Aggregates Increase the Conductance of Substantia Nigra Dopamine Neurons, an Effect Partly Reversed by the KATP Channel Inhibitor Glibenclamide. eNeuro. vol 8. issue 1. 2021-06-18. PMID:33229413. |
α-synuclein aggregates increase the conductance of substantia nigra dopamine neurons, an effect partly reversed by the katp channel inhibitor glibenclamide. |
2021-06-18 |
2023-08-13 |
Not clear |
| Maria Regoni, Letizia Zanetti, Stefano Comai, Daniela Mercatelli, Salvatore Novello, Federica Albanese, Laura Croci, Gian Giacomo Consalez, Andrea Ciammola, Flavia Valtorta, Michele Morari, Jenny Sasson. Early Dysfunction of Substantia Nigra Dopamine Neurons in the ParkinQ311X Mouse. Biomedicines. vol 9. issue 5. 2021-06-15. PMID:34063112. |
early dysfunction of substantia nigra dopamine neurons in the parkinq311x mouse. |
2021-06-15 |
2023-08-13 |
mouse |
| Lorena Jiménez-Sánchez, Javier Blesa, Natalia L Del Rey, Mariana H G Monje, José A Obeso, Carmen Cavad. Serotonergic innervation of the striatum in a nonhuman primate model of Parkinson's disease. Neuropharmacology. vol 170. 2021-06-03. PMID:31589886. |
parkinson's disease (pd) is characterized by dopaminergic neurodegeneration in the substantia nigra and dopamine depletion in the striatum. |
2021-06-03 |
2023-08-13 |
monkey |
| J Mašková, D Školoudík, P Štofaniková, V Ibarburu, D Kemlink, D Zogala, J Trnka, R Krupička, K Šonka, E Růžička, P Duše. Comparative study of the substantia nigra echogenicity and Sleep medicine. vol 70. 2021-05-31. PMID:32403038. |
comparative study of the substantia nigra echogenicity and hyperechogenicity of the substantia nigra (sn) and abnormal dopamine transporter-single-photon emission computed tomography (dat-spect) are biomarkers commonly used in the assessment of prodromal synucleinopathy. |
2021-05-31 |
2023-08-13 |
human |
| Jingyi He, Guofu Zhu, Guoqing Wang, Feng Zhan. Oxidative Stress and Neuroinflammation Potentiate Each Other to Promote Progression of Dopamine Neurodegeneration. Oxidative medicine and cellular longevity. vol 2020. 2021-05-28. PMID:32714488. |
progressive loss of dopamine (da) neurons in midbrain substantia nigra is considered to be the main cause of pd. |
2021-05-28 |
2023-08-13 |
Not clear |
| V N Salkov, R M Khudoerko. [The role of aluminum and lead in the development of Alzheimer's and Parkinson's diseases]. Arkhiv patologii. vol 83. issue 3. 2021-05-28. PMID:34041898. |
the accumulation of ions of these metals in the brain structures leads to chronic intoxication that is manifested by the morphological signs that are typical for alzheimer's disease, such as deposits of β-amyloid and τ-protein mainly in the frontal and temporal regions of the cortex, and for parkinson's disease, such as degeneration of dopamine neurons in the substantia nigra and their accumulation of α-synuclein. |
2021-05-28 |
2023-08-13 |
human |
| Hunday Govindasamy, Sivanandam Magudeeswaran, Kumaradhas Pooman. Identification of novel flavonoid inhibitor of Catechol-O-Methyltransferase enzyme by molecular screening, quantum mechanics/molecular mechanics and molecular dynamics simulations. Journal of biomolecular structure & dynamics. vol 38. issue 18. 2021-05-25. PMID:31779524. |
the low level of dopamine at substantia nigra (mid-brain) has been considered to be one of the reasons for parkinson's disease (pd). |
2021-05-25 |
2023-08-13 |
Not clear |